Onyx Shuts Down $10 Bln Offer - Presented by: The Aol. On Network

Shares of Onyx Pharmaceutical soaring after it received- and rejected a $10 billion takeover offer from biotech Amgen. Its shares were already up 31 percent over the past 12 months. Onyx says Amgen's offer of $120 a share is too low. That offer represents a premium of 38 percent based on Onyx's closing price on Friday. And Onyx may have a point. Deutsche Bank analyst Robin Karnauskas says in a note: "From our M&A valuation, we expect higher bids for Onyx of at least $140."



Related Videos

Most Popular Videos

Latest Videos


Most Active by Volume

Company Last Sale Change Net / %
BAC $ 15.65 0.29 ▼ 1.82%
AAPL $ 109.27 1.10 ▼ 1.00%
AA $ 9.49 0.08 ▼ 0.84%
QQQ $ 102.16 1.23 ▼ 1.19%
XIV $ 22.75 1.78 ▼ 7.26%
MSFT $ 42.61 0.89 ▼ 2.05%
GE $ 24 0.51 ▼ 2.08%
MU $ 16.82 0.23 ▲ 1.39%

As of 9/4/2015, 04:15 PM